AKAN
Price
$3.45
Change
-$0.09 (-2.54%)
Updated
Sep 5 closing price
Capitalization
2.58M
EAPIF
Price
$3.09
Change
-$0.56 (-15.34%)
Updated
Aug 6 closing price
Capitalization
325.72M
Interact to see
Advertisement

AKAN vs EAPIF

Header iconAKAN vs EAPIF Comparison
Open Charts AKAN vs EAPIFBanner chart's image
Akanda
Price$3.45
Change-$0.09 (-2.54%)
Volume$21.38K
Capitalization2.58M
EUROAPI SA
Price$3.09
Change-$0.56 (-15.34%)
Volume$292
Capitalization325.72M
AKAN vs EAPIF Comparison Chart in %
Loading...
AKAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EAPIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKAN vs. EAPIF commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKAN is a Hold and EAPIF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (AKAN: $3.45 vs. EAPIF: $3.09)
Brand notoriety: AKAN and EAPIF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AKAN: 18% vs. EAPIF: 25%
Market capitalization -- AKAN: $2.58M vs. EAPIF: $325.72M
AKAN [@Pharmaceuticals: Generic] is valued at $2.58M. EAPIF’s [@Pharmaceuticals: Generic] market capitalization is $325.72M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKAN’s FA Score shows that 0 FA rating(s) are green whileEAPIF’s FA Score has 0 green FA rating(s).

  • AKAN’s FA Score: 0 green, 5 red.
  • EAPIF’s FA Score: 0 green, 5 red.
According to our system of comparison, both AKAN and EAPIF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKAN’s TA Score shows that 3 TA indicator(s) are bullish while EAPIF’s TA Score has 2 bullish TA indicator(s).

  • AKAN’s TA Score: 3 bullish, 5 bearish.
  • EAPIF’s TA Score: 2 bullish, 2 bearish.
According to our system of comparison, EAPIF is a better buy in the short-term than AKAN.

Price Growth

AKAN (@Pharmaceuticals: Generic) experienced а -5.74% price change this week, while EAPIF (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EAPIF($326M) has a higher market cap than AKAN($2.58M). EAPIF YTD gains are higher at: 2.890 vs. AKAN (-31.000). AKAN has higher annual earnings (EBITDA): -3.03M vs. EAPIF (-34.7M). EAPIF has more cash in the bank: 73M vs. AKAN (3.84M). AKAN has less debt than EAPIF: AKAN (353K) vs EAPIF (69.1M). EAPIF has higher revenues than AKAN: EAPIF (919M) vs AKAN (837K).
AKANEAPIFAKAN / EAPIF
Capitalization2.58M326M1%
EBITDA-3.03M-34.7M9%
Gain YTD-31.0002.890-1,073%
P/E RatioN/A7.92-
Revenue837K919M0%
Total Cash3.84M73M5%
Total Debt353K69.1M1%
TECHNICAL ANALYSIS
Technical Analysis
AKANEAPIF
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
33%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
35%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
38%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
35%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
22%
Advances
ODDS (%)
Bullish Trend about 1 month ago
83%
N/A
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
31%
View a ticker or compare two or three
Interact to see
Advertisement
AKAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EAPIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DGIFX26.34N/A
N/A
Disciplined Growth Investors
ETLCX15.18N/A
N/A
Eventide Large Cap Focus C
SHPAX19.27N/A
N/A
Saratoga Health & Biotechnology A
IUESX29.01N/A
N/A
JPMorgan International Focus I
PRJAX46.43N/A
N/A
PGIM Jennison Global Opportunities A

AKAN and

Correlation & Price change

A.I.dvisor tells us that AKAN and SCYX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AKAN and SCYX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKAN
1D Price
Change %
AKAN100%
-2.54%
SCYX - AKAN
31%
Poorly correlated
+2.43%
TLRY - AKAN
26%
Poorly correlated
+3.48%
CRON - AKAN
25%
Poorly correlated
N/A
SNOA - AKAN
25%
Poorly correlated
+4.42%
ANIK - AKAN
24%
Poorly correlated
-1.65%
More

EAPIF and

Correlation & Price change

A.I.dvisor tells us that EAPIF and HLN have been poorly correlated (+14% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EAPIF and HLN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EAPIF
1D Price
Change %
EAPIF100%
N/A
HLN - EAPIF
14%
Poorly correlated
-0.41%
HLNCF - EAPIF
11%
Poorly correlated
-0.61%
IXHL - EAPIF
7%
Poorly correlated
-9.48%
STEK - EAPIF
6%
Poorly correlated
-3.45%
AKAN - EAPIF
2%
Poorly correlated
-2.54%
More